Browse by ▼

Roche Holding Ltd. (ADR)

  • Companies Invest in Antibodies That Fight Tumors

    By Eileen Rojas - May 13, 2013 | Tickers: IMGN, RHHBY, SGEN

    In the war against cancer, a new weapon holds promise to treat the disease in a novel way. ADCs, or antibody drug conjugates, use antibodies linked to potent anti-cancer therapeutic agents that deliver a better way of killing cancerous cells while minimizing side effects for patients. Clinical trials currently underway have so far shown very promising results.

    How do ADCs work?

    According to Dr. Marco Timmers, CSO at Synthon Biopharmaceuticals more »

  • Building a Stronger Core With Abbott Laboratories

    By Justin Carley - April 30, 2013 | Tickers: ABT, ABBV, MJN, MDT, RHHBY

    It has been more than a 100 days since Abbott Laboratories (NYSE: ABT) separated its research-based pharmaceutical business into a newly formed entity named AbbVie (NYSE: ABBV). As is often the case, the spin-off has been the initial winner. AbbVie has produced a total return of more than 32% in pretty quick order. Abbott has done well, but the 17% return has clearly not kept pace. AbbVie is now a more »

  • This Deal Brings Benefits Along With a Huge Debt

    By Shas Dey - April 29, 2013 | Tickers: ILMN, LIFE, RHHBY, TMO

    The rumors have finally been put to rest. After three months of a bidding war, Thermo Fisher Scientific (NYSE: TMO) ultimately beat other contenders to acquire Life Technologies (NASDAQ: LIFE) for $76 per share, or approximately $13.6 billion (plus net debt at close).

    This transaction, expected to be completed in 2014, is expected to propel the growth of Thermo Fisher in the area of genetic analysis and molecular diagnostics more »

  • Thermo Fisher – Life Technologies Deal Brings Benefits Along With A Huge Debt

    By Shas Dey - April 18, 2013 | Tickers: ILMN, LIFE, RHHBY, TMO

    On 15th April, Thermo Fisher Scientific (NYSE: TMO) announced that it would acquire Life Technologies (NASDAQ: LIFE) for $76 per share, 12% above its 12thApril share price of $68.

    The Deal

    After months of speculation of takeover, Life Technologies accepted Thermo Fisher’s bid over an offer from Sigma-Aldrich and a $65 per share bid from a consortium including Blackstone, Carlyle, KKR and Temasek Holdings. The price more »

  • Does Spectrum's Q4 Earnings Make It a Buy?

    By Shas Dey - April 1, 2013 | Tickers: BIIB, RHHBY, SPPI

    On 03/12/13, Spectrum Pharmaceuticals (NASDAQ: SPPI) announced its Q42012 results, and its shares declined 35% to $8, setting a new low for the company.

    Spectrum is a biotechnology company with integrated commercial and drug development operations with a focus in hematology and oncology. It markets three oncology drugs: Fusilev, Folotyn, and Zevalin. It has a strong track record of licensing and acquiring differentiated drugs. It also has a more »

  • Pharmas Hope to Grow Fat With Obesity Drugs

    By Tony Daltorio - January 10, 2013 | Tickers: ARNA, ESALY.PK, OREX, RHHBY, TKPYY.PK, VVUS

    Pharmaceutical companies have had some recent lean years thanks to the patent cliff and other factors. But some pharma companies hope to grow fat with profits again soon. 

    Their plan to do that? Jumping on the growing global trend of obesity. Pharmaceutical firms believe consumers are moving away from fad diets and look forward to a surge in sales from prescription medicines that promise to help consumers lose weight. 

    In more »

  • The Smart Money Has Been Eying the Future of DNA Sequencing: Should You?

    By Brendan O'Boyle - January 8, 2013 | Tickers: ILMN, LIFE, RHHBY

    Roche (NASDAQOTH: RHHBY) has a remarkable history of making attractive and well-timed acquisitions.  In 2009 they purchased Genentech and bought one of the most attractive companies on the market as blood ran through the streets. Recently Roche has turned its interest to a little known sequencing company named Illumina (NASDAQ: ILMN), but over this weekend they appear to have withdrawn the offer for a second time.

    In this context, it more »

  • Illumina: Buying, Selling, or Riding Solo?

    By Brian Nichols - January 7, 2013 | Tickers: GNOM, ILMN, RHHBY

    Illumina (NASDAQ: ILMN) has definitely been at the center of some of the stranger acquisition rumors of the last year. Though these rumors have made the stock volatile, it has outperformed. However, the speculation might have much more clarity after news on Sunday indicates that Roche (NASDAQOTH:RHHBY) will no longer be looking to buy the company.

    In a nutshell, here’s the story with Illumina: The company is for more »

  • Epigenetics: A 21st Century Science with Huge Investment & Medical Implications

    By BA McKenna - January 7, 2013 | Tickers: CELG, ILMN, JNJ, MRK, RHHBY

    Epigenetics?? I don’t need to know about what sounds like a specialized form of genetics as it’s too technical for me the big-picture investor, leave such detail to lab rats, some might be thinking?

    You know what Darwin said -- and if you want to be among the "fittest" biotech investors, you need to know about epigenetics. This science is not only fascinating, it is here and exploding more »

  • Roche Leads Pack for Upcoming FDA Approvals

    By Tedra DeSue - January 7, 2013 | Tickers: AVEO, DCTH, IMGN, RHHBY

    Several drugs that could be used to treat cancer patients are slated for approval by the U.S. Food and Drug Administration (FDA) during the first half of the year. Some of the manufacturers of these treatments are touting the medicines as being the next break through in treating the various forms of the deadly disease. This gives them the chance to continue to expand their presence in the multi-billion more »

  • A Bio-Pharmaceutical With Huge Upside Potential

    By Mohsin Saeed - January 7, 2013 | Tickers: GALE, PFE, RHHBY, TEVA

    Galena BioPharma (NASDAQ: GALE) has shared excellent clinical trial results for NeuVax. The stock is trading well below analysts’ consensus mean target price and, I believe, offers a huge return to investors.

    Galena has already attracted two Big Pharma partners, namely Roche and Teva Pharmaceuticals (NYSE: TEVA). I believe that the interest of big pharma warrants much higher valuations for this stock. The company has the potential to be acquired more »

  • Three Safe and Undervalued Dividend Stocks from Europe

    By Anh HOANG - December 28, 2012 | Tickers: RHHBY, VLKAY, WPPGY

    As Warren Buffett said: “Be fearful when others are greedy, be greedy when others are fearful.” The European sovereign debt crisis could create great investment opportunities for patient investors. On the article “Europe On Sale”, released by Barron’s, Jonathan Buck pointed out 10 European stocks which could potentially increase as much as 20% next year. However, I think there are five stocks in that list that can be considered more »

  • Pfizer’s Backing Spurs Halozyme's Growth

    By Josef Ray Dagatan - December 27, 2012 | Tickers: BAX, HALO, PFE, RHHBY, VPHM

    An upcoming partnership with pharmaceutical giant Pfizer undoubtedly boosted the reputation of Halozyme Therapeutics (NASDAQ: HALO), allowing it to regain market standing via its proprietary Enhanze technology. Intraday trading this past Friday, December 21, saw shares rise around thirty percent, and prices grow by almost the same percentage when it went up by $1.49 and closed at $7.01, making it the day’s top-dollar gainer.

    The licensing agreement more »

  • “I Was a Frustrated Trader”

    By Nick Slepko - December 19, 2012 | Tickers: ETFC, OTCM, OXBC, RHHBY

    R. Cromwell Coulson is President, CEO, and a Director of OTC Markets Group (OTCQX:OTCM)(NASDAQOTH: OTCM). In 1997, Cromwell led a group of investors in acquiring OTC Markets Group’s predecessor business, the National Quotation Bureau. Cromwell led the transformation of what was an opaque and inefficient market into a technology-driven Open, Transparent, and Connected marketplace platform.  Currently, two-thirds of all US public companies trade on OTCQX, OTCQB, and more »

  • Should You Buy Into the Anti-Obesity Drug Craze?

    By Jordo Bivona - December 19, 2012 | Tickers: ARNA, OREX, RHHBY, VVUS

    The American Journal of Preventive Medicine thinks that by 2030, 42 percent of U.S. adults could be obese, which would add approximately $550 billion to healthcare costs. The Centers for Disease Control and Prevention (CDC) earlier this year reported that 35.7 percent of U.S. adults and 16.9 percent of children (age 2 to 19) are obese. Two anti-obesity drugs were approved by the FDA in 2012 more »

  • Ominous Competition For Lucentis and Eylea

    By Richard Allen - November 23, 2012 | Tickers: AMPE, NVS, REGN, RHHBY

    Lucentis from Roche (NASDAQOTH: RHHBY) and Novartis (NYSE: NVS), and Eylea from Regeneron (NASDAQ: REGN) were recently approved by the FDA and combined are already producing revenues of close to $2.5 billion.  The shares of Roche and Novartis may be down a bit from their recent highs one month ago, but Regeneron continues to streak to new highs and give shareholders a spectacular ride.

    Lucentis and Eylea are both more »

  • Game Changer in Hospital Labs?

    By Robert Zimmerman - November 19, 2012 | Tickers: ABT, BDX, CPHD, VIVO, RHHBY

    Some researchers estimate that roughly 90% of all bacteria found in or on human beings cannot be cultured.  Treponema pallidum, better known as syphilis, represents a prime example.  Currently, the only way to grow syphilis is by inoculating a living animal, such as a hamster.  Rest assured, few hospitals have the resources to routinely diagnose a patient with syphilis, or any other disease, using lab animals.  Currently, diagnosing syphilis relies more »

  • Slaying the Alzheimer Demon

    By Karen Rogers - September 13, 2012 | Tickers: BAX, ELN, PFE, RHHBY

    This morning a husband woke up and couldn’t recognize his wife’s face.  An elderly mother stares blankly at her daughter, vainly trying to remember her child’s name. 

    This is the evil of Alzheimer’s, an insidious disease which robs families and friends of their loved ones while they’re still alive.  According to the Alzheimer Association, it will afflict more than 5.4 million Americans this year more »

  • How Global Growth of Cancer Can Make You Money

    By Ron Chatterjee - August 28, 2012 | Tickers: ABT, BMY, JNJ, MELA, RHHBY

    That sounded to be rather rude, eh?

    But to be honest, cancer is one of the most feared diseases of all (A February 2011 study conducted by Harris Interactive for MetLife Foundation found that 41% of Americans shudder when they hear the word "cancer"). According to the National Institutes of Health (NIH), medical costs due to cancer in 2007 are reported at around $226.8 billion, and we have over more »

  • Regeneron's Vision for the Future

    By Jonathan Lim - August 27, 2012 | Tickers: ALPMY.PK, BAYRY.PK, REGN, RHHBY, SNY

    "Great company, but not at that price" is a line I use a lot these days. It sure can be tempting to deviate from a value-focused strategy, especially when all sorts of glamorous growth stories are commanding billion-dollar valuations and your Benjamin Graham cigarette-butt stocks aren’t featured on CNBC every day and aren’t sending you glossy annual reports full of exciting news. But I’m managing to stick more »

  • Page 1 of 2